Mirtazapine has been prescribed off-label to fibromyalgia patients who have not responded to other treatments. However, a recent systemic review found no difference between mirtazapine and placebo for these patients, and any potential benefits from mirtazapine may not outweigh its potential harm, including drowsiness, weight gain and liver damage…
Central Sensitization to Pain May Not Predict Long-Term Outcomes after Carpal Tunnel Release Surgery
Pain sensitization, such as that experienced by patients with carpal tunnel syndrome (CTS), has been associated with poorer clinical outcomes after surgery. New research has found that, although pain sensitization in CTS patients correlates with preoperative symptom severity, CTS symptoms did not have a persistent effect on functional outcomes after surgery…
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
After meeting with the FDA, the makers of intravenous meloxicam plan to resubmit the treatment’s new drug application…
Pain Response to Low Intensity Pressure Tied to Cognitive Deficits in Fibromyalgia
A recent study found that the perception of experimentally induced pain is closely associated with neurocognitive symptoms, such as attention, memory and executive function, in fibromyalgia patients. Specifically, fibromyalgia patients described low-intensity pressure as more painful than controls did…
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
Art Tours May Have Analgesic Effect for Chronic Pain Patients
(Reuters Health)—Art museums may have an analgesic effect on chronic pain, a small study suggests. Chronic pain sufferers who took guided tours of art museums felt less discomfort and unpleasantness related to their pain shortly afterward, researchers found. The researchers invited 54 visitors to the Crocker Art Museum in Sacramento, Calif., who reported experiencing chronic…
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…
How Depression Affects the Cognitive Profile of Fibromyalgia Patients
New research evaluated the effect of depression on the cognition of fibromyalgia patients, finding that these patients have a distinct cognitive profile. Researchers note that emotional symptoms, such as depression and anxiety, are essential to the cognitive performance of fibromyalgia patients and that treating these symptoms may reduce cognitive impairment…
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 25
- Next Page »